NCT07842692Not yet recruiting
Serum Endocan Levels in Colorectal Cancer
Serum Endocan Levels Measured by ELISA in Colorectal Cancer: Relation to Clinicopathological Features
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
This case-control study aims to measure serum endocan levels in patients with colorectal cancer and healthy controls using ELISA and to compare the levels between the two groups.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 64 (estimated)
- First submitted
- 21 Sept 2026
- Start date
- 26 Sept 2026
- Primary completion date
- 26 Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Colorectal cancer
- NCT number
- NCT07842692
What you commit to
- Study type: Observational
- Planned participants: 64
- From 26 Sept 2026 to the primary completion date, 26 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous chemotherapy or radiotherapy for colorectal cancer
Other illness
- \- Previous malignancy
- Active infection
- Autoimmune disease
- Chronic liver disease
- Chronic kidney disease
Other
- Pregnancy
Who the study is looking for
- \- Age 18 years or older
- Newly diagnosed colorectal cancer confirmed by histopathology (cases)
- No previous surgery, chemotherapy, or radiotherapy for colorectal cancer
- Healthy adults with no history of cancer or inflammatory bowel disease (controls)
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.